IBI-60089 is IBI’s next product using Verisome® technology to enter human clinical trials. IBI-60089 is a biodegradable product for the delivery of therapeutic levels of latanoprost to the anterior chamber.
Icon Bioscience, Inc. plans to initiate a Phase 1/2 clinical trial in the second quarter of 2013 after its pre-IND meeting with the FDA scheduled for May. IBI-60089 will be indicated for the treatment of elevated intraocular pressure and glaucoma. Kinetic studies to date have demonstrated that IBI-60089 can deliver latanoprost for at least 6 months with a single intraocular injection. Millions of glaucoma patients are unnecessarily going blind due to compliance and administration issues with traditional eye drops.